Dancann Pharma

In 2024, DanCann Pharma A/S reported a revenue of DKK 7.37 million, a 21.4% increase from the previous year, with sales volumes rising by 18.5% to 17,027 units. The company's EBITDA deficit was reduced by 60.2% to DKK -5.13 million. DanCann secured approximately 26.3 MDKK in financing, resulting in a net financing of 6.7 MDKK and becoming debt-free by year-end. The cash position improved to DKK 3.47 million as of December 31, 2024. Strategically, the company focused on a lean, asset-light model, concentrating on cannabinoid-based medicines. There was growth in their Rx portfolio and progress in product development, including submissions to the Danish Medicines Agency. The Danish Pilot Programme for medicinal cannabis was confirmed as permanent. For 2025, DanCann anticipates revenue between DKK 10.0 to 12.5 million and an EBITDA of DKK -4.0 to -6.0 million. They plan to expand product offerings and pursue operational efficiencies to enhance shareholder value. DanCann Pharma A/S, founded in 2018, is a Danish biopharmaceutical company listed on the Spotlight Stock Market. The release includes forward-looking statements subject to risks and uncertainties, and the company advises caution in relying on these statements.

DanCann Pharma A/S har meddelat att deras årsredovisning för 2024 och årsstämman för 2025 har blivit uppskjutna. Årsredovisningen och kallelsen till årsstämman kommer nu att släppas den 4 april 2025, och årsstämman hålls den 24 april 2025. Företagets finansiella kalender har uppdaterats för att återspegla dessa ändringar. DanCann Pharma A/S är ett danskt läkemedelsföretag grundat 2018, specialiserat på cannabinoider och noterat på Spotlight Stock Market. För mer information kan man kontakta företagets VD, Jeppe Krog Rasmussen.

DanCann Pharma and Tetra Pharm Technologies have entered into a three-year agreement, with the possibility of extension, to integrate Tetra Pharm's ZYNDIKATE® drug delivery technology into DanCann's products. This technology is designed to improve the absorption and effectiveness of lipophilic molecules, such as cannabinoids, in the bloodstream. Both companies aim to expand this collaboration across the Nordic markets. The first product using this technology is expected to be available to Danish patients in the first half of 2026. DanCann Pharma focuses on cannabinoid-based medicines, while Tetra Pharm specializes in drugs for neurological and mental health disorders. The partnership seeks to enhance treatment quality and broaden the range of available therapies. The announcement includes forward-looking statements, which are subject to risks and uncertainties that could impact actual outcomes.

At an extraordinary general meeting on January 21, 2025, DanCann Pharma A/S decided to change the nominal value of its shares from DKK 0.001 to DKK 1 through a reverse share split at a 1,000:1 ratio. Consequently, 1,000 shares of DKK 0.001 each are consolidated into one share of DKK 1. A redemption notice was issued, giving shareholders four weeks, until February 19, 2025, to redeem shares. Shares below 1,000 or excess shares will be redeemed in cash at DKK 0.0023 per share. Payments are expected by February 26, 2025, and will be subject to withholding tax. Shareholders can contest the redemption price by May 26, 2025. The new nominal share value takes effect on February 25, 2025, with a new ISIN DK0063631999. The company's share capital will consist of 3,991,101 shares of DKK 1 and 234 shares of DKK 0.001 held by the company. Key dates include the last trading day of old shares on February 21, 2025, and the first trading day of new shares on February 24, 2025.

The legislative proposal L135, published on February 6, is set for its first reading on February 21, 2025. DanCann Pharma emphasizes the importance of making their observations and proposals public to enhance understanding of the proposed legislation and industry challenges. CEO Jeppe Krog Rasmussen stresses the need for consensus and improved regulatory frameworks, highlighting that the proposal has many unresolved issues. The company aims to provide transparency and secure favorable outcomes for stakeholders. Their consultation response reflects DanCann Pharma Group's views, including its subsidiary CannGros ApS, and includes several attached documents in Danish. DanCann Pharma, established in 2018 and listed on the Spotlight Stock Market, focuses on cannabinoid-based biopharmaceuticals. The release contains forward-looking statements subject to risks and uncertainties, and the company advises caution in relying on these statements.

Den 6 februari offentliggjordes ett reviderat lagförslag (L135) som kommer att behandlas den 21 februari 2025. DanCann Pharma betonar vikten av att offentliggöra sina observationer och förslag för att öka förståelsen för lagförslaget och de utmaningar som branschen möter. CEO Jeppe Krog Rasmussen påpekar behovet av att belysa problemområden för att skapa enighet och rättvisa regler inom industrin. Han framhåller att det är viktigt att ge allmänheten insikt i de utmaningar företaget står inför och att målet är att uppnå bästa möjliga resultat för intressenter. DanCann Pharmas synpunkter representeras av deras dotterbolag CannGros ApS och dokument med kommentarer och rekommendationer har bifogats i pressmeddelandet. DanCann Pharma A/S är ett danskt biofarmaceutiskt företag fokuserat på cannabinoider och är noterat på Spotlight Stock Market. Pressmeddelandet innehåller även framåtblickande uttalanden med varningar om osäkerheter och risker som kan påverka företagets framtida resultat.

Summary: The financial results for DanCann Pharma A/S for the fourth quarter of 2024 show an increase in net sales and significant improvements in EBITDA compared to the previous year. Net sales for Q4-2024 were 1,350 DKK, while the full year 2024 saw net sales of 7,764 DKK, up from 6,074 DKK in 2023. EBITDA improved by 63.8% year-over-year, moving from -12.88 million DKK in 2023 to -4.66 million DKK in 2024. The equity ratio increased to 0.90 from 0.53. CEO Jeppe Krog Rasmussen noted that the year was pivotal, with both opportunities and challenges, including increased competition and regulatory complexities. The report includes insights into strategic progress, financial potential from asset sales, cost reductions, market competition impacts, revised future guidance, and product approval status. DanCann Pharma A/S is a Danish biopharmaceutical company focused on cannabinoids, listed on the Spotlight Stock Market. The report also contains forward-looking statements with associated risks and uncertainties.